Full Title
A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid TumorsPurpose
Researchers want to find the best dose of LY3962673 that can be used safely in people with advanced solid tumors. The people in this study have tumors that have metastasized (spread) or are inoperable (cannot be taken out with surgery). They include people with colorectal cancer, non-small cell lung cancer, and pancreatic cancer.
In addition, their tumors must have a specific mutation (change) in the KRAS gene called G12D, which can drive cancer cell growth. LY3962673 is designed to block the activity of the KRAS G12D-mutated form of the protein.
By targeting this mutation, LY3962673 may help slow or stop the growth of your cancer. This medication is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a metastatic or inoperable solid tumor with a KRAS G12D mutation. The tumor must keep growing after treatment.
- Have recovered from the serious side effects of prior therapies before taking LY3962673.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Anupriya Singhal’s office at 646-888-4302.
Protocol
25-037
Phase
Phase I (phase 1)
Disease Status
Newly Diagnosed & Relapsed/Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06586515